This study is in progress, not accepting new patients
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
Summary
- Eligibility
- for people ages 18-60 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Meyeon Park
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Meyeon Park
My research focuses on the early diagnosis of kidney hypoxia, injury, and disease and the influence of cardiovascular disease on kidney disease onset and progression. Clinically, I see patients with all manifestations of hypertension and kidney disease, with a special focus on patients with polycystic kidney disease.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Kadmon Corporation, LLC
- ID
- NCT03203642
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated